HSIC

🏥 Healthcare

Henry Schein, Inc.

Conservative #295Aggressive #394Low RiskModerate 71

Market Cap

$9.5B

P/E Ratio

24.7

Sector avg: 252.3

Rev Growth

2.7%

Sector avg: 161.5%

Earnings Growth

-6.3%

Profit Margin

3.1%

Sector avg: -3292.7%

Debt/Equity

0.85

Why This Score

HSIC scores 60.4 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.

Strengths

High conviction (71/100) — fundamental and ML signals agree on this stock.

No material penalties applied. HSIC ranks #295 based on its factor profile and ML signal alignment.

Score Breakdown

Overall Score60.4

Fundamental Score53.4

ML Score69.0

Score by Horizon

3 Month

76.2

6 Month

85.2

Primary

1 Year

89.7

Quality Assessment

Earnings Grade

Strong fundamentals, high earnings quality

Position Sizing

Suggested Allocation

Confidence

high

Score Composition Waterfall

How each component affects the final score

Backtested Scoring Levers (IC-calibrated from 30y ElasticNet)

Weinstein (12.1%)

100

Advancing

Sentiment (2.5%)

Neutral

Analyst (6.4%)

Neutral

Tradability (post-hoc)

Grade A

Base

56.5

SHAP

+2.9

Factors

+1.1

Divergence

-0.1

Final

60.4

Positive adjustment

Negative adjustment

Base blend

Final score

Factor Breakdown

Value70

Quality55

Growth45

Stability60

Investment80

Signal SegmentsComputed from ML features

Fundamental (Valuation, Quality, Growth)45.0

Technical (Momentum, Weinstein, Volatility)76.0

External (Sentiment, Analyst, Macro)77.0

Scores below 50 indicate weakness in that segment relative to the universe.

Data Quality

Score

Features

Confidence

Feature Coverage96%

Growth Estimates

Short-term

+4.6% to +9.7%

Medium-term

+7.9% to +15.6%

Long-term

+11.6% to +22.2%

ML Model Core Features100 trained inputs → ML Score: 69

These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.

Analyst Intelligence

Consensus Score58.9/100

Target Upside+7.9%

Coverage31 analysts

Market Sentiment

Sentiment Score48.4/100

News Volume1 articles

Technical Stage

Weinstein Stage2 — Advancing

12M Momentum+0.1%

6M Momentum+0.1%

Volatility+0.1%

Momentum & Technical

Momentum Acceleration-4.0%

Momentum ConsistencyModerate (0.67)

Relative Strength vs Sector-16.1%

Trend Strength (ADX Proxy)Weak (1.2)

Momentum Quality+0.072

Momentum BreadthBroad ✓

Macro Regime

Bull RegimeYes

High Vol RegimeNo

S&P 500 Return+25.0%

Yield Curve-0.1bp

Sector-Relative AnalysisIn-model features

Value Trap Signal

11%

Low risk

Sector RevGr Rank

P46

Revenue growth vs Healthcare peers

Sector PE Rank

P21

Valuation vs Healthcare peers

Sector FCF Rank

P94

Free cash flow vs Healthcare peers

Growth Deviation

-0.0σ

Z-score vs sector median

Stagnation Flag

Not flagged

Analysis Signals

Scoring Factors

Fundamental score of 66 relative to sector peers66/100

Machine learning model ranks this stock at the 80th percentileP80

ML model weight reduced to 9% due to macro conditions: market in extended rally phase; yield curve inverted (recession indicator); late-cycle economic indicators detected9% ML weight

SHAP feature alignment: +3.7pt (features align with model priorities)—

Blend: 91% fund (65.5) + 9% ML (79.8) + SHAP(+3.7) = 70.5—

Factor quality: +1.4pt (multi-factor composite)—

Risk assessment: low. Annualized volatility 6.9%. Stability bonus of +8.3 points. Max drawdown 13% (-2.2 pts)Low

Market cap adjustment: +0.5 points ($9.5B market cap)+0.5 pts

Risk Factors

No risk factors identified.

Sector Peer Comparison(Healthcare — Rank #37 of 344 stocks)

Stock	Score	P/E	Rev Growth	Margin	Mkt Cap
HSICHenry Schein, Inc.	60.4	24.7	2.7%	3.1%	$9.5B
INCYIncyte Corporation	89.6	15.8	21.2%	25.0%	$20.1B
GMABGenmab A/S	85.5	13.1	22.8%	36.4%	$18.5B
CPRXCatalyst Pharmaceuticals, Inc.	82.2	13.7	23.5%	37.6%	$3.0B
VRTXVertex Pharmaceuticals Incorpor	78.0	32.1	8.9%	32.9%	$126.0B
ASNDAscendis Pharma A/S	75.7	16.6	98.0%	-31.7%	$13.3B
NBIXNeurocrine Biosciences, Inc.	74.7	26.5	21.4%	16.7%	$12.5B
ALKSAlkermes plc	74.6	16.5	-6.4%	23.9%	$5.5B
AMGNAmgen Inc.	73.8	26.0	10.0%	21.0%	$199.0B
ARGXargenx SE	73.6	35.1	78.6%	38.0%	$50.9B
HOLXHologic, Inc.	73.3	31.1	1.7%	13.8%	$16.8B
REGNRegeneron Pharmaceuticals, Inc.	72.7	19.4	1.0%	31.4%	$84.9B
ISRGIntuitive Surgical, Inc.	72.3	61.7	20.5%	28.4%	$172.5B
EXELExelixis, Inc.	71.9	15.1	7.0%	33.7%	$11.7B
KRYSKrystal Biotech, Inc.	71.0	41.4	473.0%	30.7%	$8.0B
HALOHalozyme Therapeutics, Inc.	70.2	16.8	22.4%	43.7%	$9.3B
Sector Average	37.1	252.3	161.5%	-3292.7%	—

Market Sentimentvia FMP

No analyst sentiment data available for HSIC.

Why This Stock

HealthcareP/E ratio of 24.7Earnings quality grade AValuation below sector median (P/E 24.7)

Tradability FilterGrade A — 93/100Score impact: -10.9pt

Volume

100

1.2M avg/day

Dollar Vol

100

$99M/day

Float

98M shares

Mkt Cap

$9.5B

Range

37% spread

Composite Liquidity Score93/100

FDCBA

Multi-Year Range Analysis

Sideways: 38/100

Year	Low	High	Range	Status
2021	$60.70	$83.45	31.6%	Moderate
2022	$64.75	$92.68	35.5%	Wide
2023	$60.01	$89.72	39.7%	Wide
2024	$63.67	$82.63	25.9%	Moderate
2025	$60.56	$82.49	30.7%	Moderate

3-Year Range

39.7%

Narrow Years

1 / 5

Sideways Penalty

None

Free Float

80.6%

Outstanding Shares

121M

Bid-Ask Spread

37.0%

Institutional Tradable

Yes

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.